T he majority of cancer patients present with advanced disease. Often, the primary tumor mass can be resected, although surgery usually cannot be used to remove disseminated metastases that are frequently responsible for ultimate patient demise. Agents capable of treating such disseminated disease must have a high therapeutic index, showing selective toxicity against cancer tissue while sparing normal cells. Gene therapy is one very promising approach because targeting to cancer cells can be combined with intracellular mechanisms regulating selective expression to achieve good tumor specificity. Tumor-selective activity can be used to regulate very great toxicity, either through the amplification intrinsic in producing a gene product from even a single gene copy, or by using a conditionally replicating system to kill infected cells.
Adenovirus is one of the most promising vectors for cancer gene therapy, and the development of a form that can be administered systemically and targeted to disseminated tumors is one of the major challenges facing cancer gene therapy. However, there are several issues to be addressed before this is likely to be a feasible approach. Most obvious is the problem of rapid clearance of virus from the blood, widely reported and discussed by several authors who have used a range of techniques to prevent unwanted entry of the virus into nontarget tissues. These approaches are discussed in detail below. Second is the question of target selectivity, where effective expression in target tissue must be combined with avoiding unwanted infection of healthy tissues in order to prevent unnecessary immune provocation and vector depletion. More fundamentally, however, are the technical issues over which assays can be meaningfully used to measure pharmacokinetics of viruses, particularly when they have been tropism ablated or retargeted to infect through novel receptors.
Techniques for the determination of adenovirus distribution kinetics
Useful performance of pharmacokinetic analyses requires adequate definition of the virus preparation being used, and understanding of the species being followed when measurements are taken. Typical adenovirus preparations have particle -to -infectivity (P /I ) ratios in the range of 10-100. The fact that P/ I ratios are usually greater than 1 partially results from the practical design of experiments used to determine it; however, most virus preparations also contain a significant component of noninfectious material. Determination of the systemic distribution of this material would clearly be misleading when trying to maximize the plasma circulation of infectious virus. Issues such as these are a problem when using physical tracing methods such as quantitative ( real -time ) polymerase chain reaction ( Q -PCR ) or radiotracing techniques. Both techniques would produce misleading results when the virus preparation contains noninfectious virus particles, whereas Q -PCR would also be vulnerable to the presence of free DNA and radiotracing to the presence of free capsid proteins. These issues are likely to be significant using most conventional preparations of adenovirus.
The obvious alternative to following the distribution of virus DNA or proteins is to use virus infectivity as the marker for biodistribution, and in many situations, this can be useful. However, it fails when components of the experimental milieu interfere with infectivity, e.g., antiadenovirusneutralizing antibodies, or where the virus of interest is tropism -ablated to prevent infection through the normal route. These different tracing techniques all find important and complementary applications, but it is essential to define precisely how individual experiments were performed before the data generated can be interpreted accurately. We have tried to bear this caveat in mind throughout interpretation of data reported in this review.
Adenovirus pharmacokinetics in mice
Animal models have illustrated that hepatic uptake of systemically injected adenovirus is very efficient. It is widely accepted that adenovirus is rapidly taken up into Kupffer cells (KCs ), significantly reducing the number of infectious virus present in the blood. One of the best studies in this field was performed by Alemany et al, 1 where the amount of infectious virus present was determined by isolating plasma and using it to infect 293 cells in vitro. These studies demonstrated that the half -life of adenovirus type 5 ( Ad5 ) in mice was less than 2 minutes. 1 A recent report has investigated virus uptake into KCs using vectors labeled with the fluorophore, Cy3. These studies indicate that low doses of adenovirus (up to 3Â10 10 viral particles ) are rapidly sequestered by KC, but higher virus doses can overcome this biological filter effect, leading to a nonlinear dose response in hepatic gene transduction. 2 The importance of the liver in determining the fate of intravenously administered adenovirus has been demonstrated by bypassing the hepatic circulation by clamping the portal vein, hepatic artery, and bile duct. While the clamp was in place, circulating plasma levels of infective virus remained constant but decreased rapidly following removal of the clamp. 3 It should be noted that all of these pharmacokinetic studies were performed in normal mice, which would not have previously been exposed to human adenoviruses. It is likely that in animals with preexisting antiadenovirus antibodies, the infectious virus in plasma would be neutralized. A recent study has investigated the effects of preimmunization on virus biodistribution in a syngeneic mouse tumor model. 4 TM -40D mouse mammary tumors were grown in BALB /C mice. Animals were immunized with an intratumoral ( i.t. ) injection of 1Â10 11 viral particles of replication -defective Ad5 lacking a trangene (Ad -null ). Two weeks later, the animals were given an i.t. injection of Ad luciferase, and virus biodistribution was examined and compared to the findings in naïve mice. As expected, preimmunization resulted in a significant decrease in luciferase gene expression in all tissues examined and also led to a fall in the duration of transgene expression. Unexpectedly, viral toxicity was noticeably greater in the preimmune animals: administration of 6Â10 11 virus particles i.t. caused death in 60% of the preimmunized group compared to just 15% of the naïve mice. The major toxicities were hepatitis and elevated liver enzymes. The increased acute toxicity observed in the preimmunized animals was unexpected as the humoral immunity was predicted to exert a protective effect against virus toxicity by inhibiting successful transduction of the liver and peripheral organs. The precise reason for greater toxicity in preimmunized animals is unclear at present, though if the effect is found to be reproducible, it may have significant implications for transfer of the approach into the clinic.
Virus retargeting strategies
Adenoviral vectors enter cells in a multistage process. First, the knob domain of fiber binds the Coxsackie and Adenovirus Receptor (CAR ), 5 followed by an interaction between the RGD motif of the penton bases with avb3 and avb5 integrins, facilitating internalization of the virus by receptormediated endocytosis. 6 More recently, the involvement of a third cell surface interaction, with heparan sulfate glycosaminoglycans (HSGs), has been demonstrated. 7, 8 CAR is widely expressed on many cell types, and it is thought that the rapid accumulation of systemically administered adenoviral vectors in the liver of mice is due to high hepatic levels of CAR and av integrins. 9 There is some disagreement regarding the effects of CAR binding on the biodistribution of systemically delivered adenoviral vectors in mice. Some studies have demonstrated that ablation of CAR binding does not alter the biodistribution or toxicity of systemically administered adenovirus in mice. 10, 11 In both studies, the biodistribution was monitored by Q -PCR and transgene expression assays. A more recent report has demonstrated that a CAR -ablated vector with the KO1 mutation in the AB loop gave higher levels of hepatic gene transduction than vectors containing wild -type fiber. 12 These data suggest that CAR binding may not be the major determinant of hepatic transduction in vivo and, therefore, that other aspects of the viral entry mechanism such as integrin or HSG binding may play a significant role. The situation is not completely clear, however, because Einfeld et al 13 described a four-aminoacid substitution in the AB loop of adenovirus fiber that decreased liver transduction 10 -fold.
To completely ablate the natural tropism of adenoviral vectors, both CAR and integrin binding sites must be mutated. Doubly ablated adenoviral vectors show up to a 700-fold reduction in luciferase gene expression in the liver following systemic administration. 13 Only Alemany and Curiel 10 examined the levels of CAR -ablated virus in the blood and showed, using a modified plasma infectivity assay, that the levels of CAR -ablated virus present in the blood were approximately 10 -fold higher than unmodified virus over a 60 -minute time period.
In order to target tumor cells specifically, CAR, integrin, and HSG binding must be abolished and replaced with a tumor-specific targeting mechanism. This can be achieved in several ways. A popular approach involves complexing the adenovirus with a bispecific molecule that blocks the interaction with CAR and redirects the virus to a novel receptor.
14 The CAR -blocking component of the bispecific molecule can be a neutralizing antibody, a soluble form of CAR, or a high -affinity peptide that binds to the knob. The receptor-binding component can be an antibody or fragment of an antibody, a high -affinity peptide, or even a small molecule that binds to the receptor. This approach has been used extensively to retarget replication-deficient adenoviral vectors. Ligands that have used in this approach include CD3, 15 E -selectin, 16 av integrins, 16 FGF receptor, 17, 18 and EGFR. 19 An alternative approach involves genetic modification of the adenovirus vector to incorporate targeting sequences, Cancer Gene Therapy Adenoviral vectors: Systemic delivery and tumor targeting NK Green and LW Seymour with the possibility of simultaneously ablating interactions of the fiber and penton base with their native receptors. High -affinity peptide ligands have been inserted into the HI loop or on to the C -terminus of fiber, into the RGD loop of penton base, or even into an exposed loop of hexon. Several peptide ligands have been identified, which are home to particular organs including vascular endothelium, 20 kidney, 21 head and neck, 22 and ovarian tumors. 23 The pharmacokinetics and biodistribution of the retargeted viruses do not appear to differ significantly from unmodified virus. The virus is cleared rapidly from the blood as determined by Q -PCR and gene expression data, and is found predominantly in the liver, with the exception of FGF2 -retargeted adenovirus, which showed 10 -to 20 -fold less liver uptake than unmodified virus controls. This decreased liver uptake translated into a significant reduction in subsequent toxicity as measured by serum transaminases and histopathology in mice. 24 Probably the most promising in vivo results to date have used adenovirus targeted with a bispecific antibody to angiotensin-converting enzyme (ACE ). 25 The vector showed at least a 20 -fold increase in viral DNA and transgene expression in the lungs compared to an untargeted virus following systemic administration in rats. Targeted gene delivery through ACE may offer new therapeutic opportunities in diseases such as pulmonary hypertension, pulmonary thromboembolic disease, and pulmonary carcinoma. However, although adenoviral vectors retargeted to infect through specific receptors give promising results in vitro and following local administration in vivo, the clearance times following intravenous administration are generally short. Bloodstream circulation must be significantly extended if the vectors are to provide any realistic platform for targeted delivery of genes to disseminated targets to mediate useful therapy.
Another approach to link targeting ligands to adenoviral vectors involves the use of polyethylene glycol (PEG ). This strategy has important implications because PEGylation also provides a degree of protection from neutralizing antibodies. Heterobifunctional PEG has been used to modify adenovirus with a peptide designed to target ciliated epithelial cells 26 and a urokinase plasminogen activator -derived peptide. 27 In both of these cases, the tropism of the vector was expanded, but native tropism was not ablated. Alemany et al 1 studied the blood clearance rate of PEGylated adenoviral vectors in BALB / C mice. Infectivity of the PEGylated virus was measured by serial dilution of plasma and infection of A549 cells. A 300 -to 1000 -fold loss of infectivity was observed using modification under the conditions defined as ''4% PEG'' and the blood clearance rate of PEGylated virus during the first 30 minutes (determined using ex vivo infectivity and corrected using the 300-1000 factor noted above ) was 4 -fold slower than for normal virus. There was no evidence of toxicity with the PEGylated virus.
Fisher et al 28 showed that polymer modification of adenoviral vectors using multivalent polymers based on poly [ N -2( hydroxypropyl )methacrylamide ] ( HPMA ) was an effective means to ablate normal virus tropism, decreasing viral transgene expression by 100 -fold. The polymercoated virus could be retargeted to infect through novel receptors using FGF2 and vascular endothelial growth factor (VEGF). The vector exhibited ligand-mediated, CAR -independent gene transfer as well as resistance to neutralizing antibodies. 28 Polymer modification results in extended blood circulation times in mice and reduces hepatic gene expression by three logs. 29 Virus levels in the blood have been measured using 125 I -labelled virus, Q -PCR, and infectivity assays. While our findings are in accord with previous reports regarding the rapid clearance of infectious virus from the circulation, our Q -PCR and radioactivity results suggest a higher proportion of inactive virus is present in whole blood than in plasma. We believe this may involve interactions between the virus and blood components including erythrocytes, and leads to the observation that kinetic studies that work with only serum or plasma may be missing a significant proportion of bloodborne virus.
Conditionally replicating vectors
The use of replicating vectors, which may only infect a small proportion of tumor cells but are designed to allow spread of the virus to neighboring cells, can significantly increase the efficacy of gene delivery coupled with direct cytolytic activity. Replication competence can be made conditional on the biology of the cell infected; e.g., key virus proteins can be placed under the regulatory control of cell -specific gene promoters, restricting virus production to the appropriate target cells. This approach is considered in more detail later. A more sophisticated system, however, has been to modify the adenovirus proteins to enable the virus to replicate only in cells that bear cancer-related phenotypes. Two main approaches have been pursued, and these are considered briefly here.
Adenoviruses deficient in E1B
Inhibition of p53 protein activity must be blocked in order to allow efficient viral replication. The 55 -kDa protein encoded by the E1B region of normal adenovirus binds and inactivates p53, allowing replication in normal cells. ONYX -015 ( dl1520 ) contains a 827 -bp deletion in the E1B region of the viral genome and a point mutation, generating a premature stop codon that prevents expression of a truncated form of the E1B -55-kDa protein. 30 It follows that infection of normal cells with ONYX -015 should generate a p53 response that leads to growth arrest or apoptosis, preventing virus replication. In contrast, tumor cells lacking a functional p53 gene should be unable to suppress viral replication. In this way, replication of ONYX -015 should be restricted to p53-deficient cells, resulting in selective destruction of cancer cells. 31 However, several recent reports indicate that ONYX -015 can replicate in a variety of tumor cell lines with wild -type p53.
32 -34 p14ARF 35 is a tumor suppressor protein that binds to Mdm2, sequestering it in the nucleolus and preventing degradation of p53. 36 A recent study has demonstrated that lack of p14ARF expression in tumors with wild -type p53 disrupts the p53 signaling pathway, leading to high and uncontrolled Mdm2 protein activities facilitating Cancer Gene Therapy Adenoviruses deficient in E1A
Other replication -competent viruses have been generated by mutating the E1A region of the adenoviral genome. KD1 and KD3 are vectors containing deletions in the E1A gene, which abolish the ability of E1A to deregulate the cell cycle and cause cells to move from G 0 to S phase. The E3 region genes that protect virus -infected cells from destruction by the immune system have also been deleted to prevent runaway viremia by the vector. These viruses can also overexpress the adenovirus death protein (ADP ), which gives them increased capacity for cell lysis and virus spread. 38 The vector can also be modified to include the tissue -specific surfactant protein B (SPB ) promoter, which is expressed in type II alveolar and bronchiolar epithelial cells.
39 KD1 -SPB replicates well in H441 papillary lung adenocarcinoma cells but very poorly in Hep3B hepatocellular carcinoma cells, which do not express SPB, and the virus has been shown to suppress growth of H441 tumors in nude mice. 40 Recently, it has been demonstrated that coadministration of KD1 or KD3 with replication -defective adenoviral vectors increases cytotoxicity and transgene expression. 41 Systemic administration of the KD vectors has not yet been reported; whereas the kinetics of the input virus would be expected to be the same as a replication-incompetent virus, any small amount of virus gaining access to permissive cells might modify the pattern of in vivo transduction considerably.
Several E1A mutant adenoviruses have been described: dl312 is totally E1 -deleted, dl101 has a deletion in the p300 -binding region, 42 whereas E1A CR -2 contains deletions in the conserved region of E1A. 43 However, a virus with a mutation in the pRB family -binding region of E1A ( dl922 -947 ) has demonstrated the best antitumor efficacy in animal models. MDA -MB-231 human breast cancer cells were injected orthotopically into nude mice, in a model system that forms metastases in the lungs and lymph nodes as well as the primary breast tumor. Mice were treated with dl922 -947, dl1520 (ONYX -015), or wild -type Ad5 by tail vein injection ( 2Â10 8 pfu daily for 5 days ). They were sacrificed when the primary tumor reached 1200 mm 3 or at 3 months, and examined for the presence of metastases. Animals treated with dl922 -947 had significantly fewer metastases ( 1/ 19) compared with dl1520 ( 12/19 ) or wt virus (6 /18 ). 44 However, no viral pharmacokinetics or biodistribution studies were performed.
Tissue -selective promoters for creation of conditionally replicating adenovirus
Replication -competent viruses can be targeted by the use of tissue -specific promoters to restrict adenoviral replication to specific tissues. Prostate -specific antigen (PSA ) is a widely used marker for the diagnosis and management of prostate cancer. Enhancer /promoter constructs derived from the 5 0 regions flanking the human PSA gene have been cloned upstream of the E1A gene to generate CN706, a prostatespecific enhancer containing provisionally replicating adenovirus. A single i.t. injection of virus led to destruction of LNCaP xenografts and abolished PSA production in a nude mouse model. 45 A phase I trial of CN706 has recently been completed in patients with locally recurrent adenocarcinoma of the prostate. Up to 10 13 viral particles were administered into the prostate using brachytherapy techniques. Treatment was well tolerated and some patients achieved biochemical ( PSA ) responses. 46 Provisionally replicating E1A mutant viruses containing the AFP promoter 47 and the DF3 /MUC1 promoter 48 have been shown to have antitumor activity in animal models of hepatocellular carcinoma and breast cancer. In these studies, the virus was administered by i.t. injection and virus biodistribution and pharmacokinetics were not addressed.
Immune responses
Another factor that needs to be addressed before adenoviral vectors can routinely be used systemically is provocation of the immune system. Most patients have previously been exposed to adenovirus and have pre -existing neutralizing antibodies. In the clinical trials using ONYX -015, the majority of patients presented with neutralizing antibodies and almost all showed a significant increase in titer after the initial virus injection. 49, 50 There are also significant concerns over vector immunogenicity following the death of a patient after hepatic artery infusion of a replication-defective Ad5 vector. 51, 52 It is thought that viral capsid proteins are involved in the acute cytokine release observed shortly after virus administration. 53 Inflammation then occurs at the site of gene transfer due to T-or B -cell -mediated targeting of transduced cells. 54, 55 A recent study has demonstrated that both neutralizing and non-neutralizing antiadenovirus antibodies are capable of activating complement. 56 Plasma from healthy volunteers was incubated with increasing doses of adenovirus and the levels of C3a measured. There was a dose -dependent activation of C3a but levels varied significantly between subjects. The report indicates that performing in vitro complement studies on patients undergoing gene therapy may be useful and suggests the use of prophylactic steroids ( to reduce subsequent inflammation ) or C1 esterase inhibitors.
Systemic delivery of adenovirus in clinical trials
The only clinical trials to date involving systemic delivery of conditionally replicating viruses are the ONYX -015 studies. The virus has been administered by hepatic artery infusion for the treatment of metastatic colorectal cancer 57 and intravenously in patients with metastatic lung tumors. 58 Both studies were dose escalation regimens. No doselimiting toxicity was identified, and the toxicity profile was not altered when the virus was coadministered with
Cancer Gene Therapy Adenoviral vectors: Systemic delivery and tumor targeting NK Green and LW Seymour chemotherapy. The most common side effects were mild to moderate fever, rigors, and a dose -dependent transient transaminitis. Neutralizing antibody titers were significantly increased. Evidence of viral replication in the blood was detectable in patients receiving virus doses >2Â10 11 particles and i.t. replication was confirmed in one patient in the intravenous delivery trial. No objective tumor responses were demonstrated with ONYX -015 alone, but a partial response and tumor stabilization were observed in patients who had been treated with high doses of ONYX -015 and chemotherapy. These studies have demonstrated that intravascular infusion of ONYX -015 was well tolerated and resulted in viral infection of metastatic pulmonary tumors and i.t. viral replication, suggesting that systemic delivery of genetically modified adenoviral vectors is a feasible approach.
Pharmacokinetic studies, using Q -PCR, were performed to detect viral genomes in plasma. In the intrahepatic artery trial, no virus could be detected after 6 hours; 57 but in the intravenous administration protocol, low levels of virus ($2Â10 6 virus particles /mL, approximately 0.3% of the total injected dose ) were detectable up to 6 hours after the end of virus infusion in patients receiving high doses of virus (2Â10 12 particles ). These studies were performed on patients that were initially antibody -negative. However, repeated administration did not seem to affect the pharmacokinetic data; virus could still be detected in the blood 6 hours after the fourth virus infusion. The titers of viral DNA were independent of dose over the range of 2Â10 10 -6Â10 11 particles. At 2Â10 12 particles and above, there appeared to be a greater plasma PCR signal, albeit not statistically significant. The half -life of the viral DNA was about 20 minutes over the first 2 hours following injection, although infectivity was not assessed, and levels did not change as a function of time from 2 to 6 hours after treatment. 58 
Key hurdles to overcome
There are several approaches that could be used to increase the clinical efficacy of the conditionally replicating viruses. Preclinical studies have demonstrated that up to 80% of ONYX -O15 is taken up into the livers of mice following intravenous injection. 49 It is likely that this figure will be even greater in humans; hence, hepatic uptake needs to be prevented in order to permit effective targeting to metastatic tumors. A previous study in mice has shown that depletion of KC using gadolinium chloride resulted in an increase in plasma virus levels and a reduction in hepatic gene expression. 1 However, it is unlikely that this approach would be used clinically.
Any virus that is delivered systemically must be protected from neutralizing antibodies present in the sera of most patients. Genetic strategies are generally inefficient at overcoming this problem, and surface modification of adenovirus with reactive hydrophilic polymers is presently the most effective way of preventing unwanted neutralization. The use of HPMA to coat replication -deficient adenovirus can reduce CAR -mediated entry into cells, ablates unwanted hepatic gene expression in mice, allows versatile retargeting, and simultaneously protects from neutralizing antibodies. 28, 29 This technique could easily be extended for use with replication-competent viruses.
New versions of the ONYX -015 that contain prodrugconverting enzymes in order to generate high local concentrations of cytotoxic compounds following systemic administration of nontoxic prodrugs have been developed. An E1B -55 kDa -deleted adenovirus has been devised, expressing the herpes simplex virus thymidine kinase ( Ad.TKRC ). 59 Ad.TKRC was evaluated in nude mice bearing subcutaneous xenografts of human A375 melanoma and ME180 cervical carcinomas. The i.t. injection of Ad.TKRC followed by treatment with ganciclovir (GCV ) resulted in a significant increase in the survival times of tumor-bearing mice. Treatment of tumors with Ad.TKRC without GCV resulted in a similar antitumor effect, confirming that the replicating vector has an oncolytic effect. These results confirm that both the oncolysis caused by a replicating virus and suicide/ prodrug gene therapy with HSVtk /GCV have potent antitumor effects. When combined, these two approaches are complementary, resulting in a significantly improved treatment outcome.
Conclusions
Improved systemic delivery of adenovirus will require novel coat modifications to prevent unwanted infection of nontarget cells, as well as evasion of neutralization by antiadenovirus antibodies. The possibility of virus interactions with blood cells should also be considered, with kinetic studies being performed in both plasma and whole blood. Identification of the viral genes and immune parameters effecting efficacy and toxicity may lead to the development of new immunomodulatory strategies, whereas clearer understanding of the synergy between replicating adenoviral vectors and chemotherapy should enable production of systemically deliverable vectors with true clinical efficacy.
